Paradoxical down-regulation of p16INK4a mRNA with





































In human biology aging is accompanied by a 
diminished capacity to adequately maintain tissue 
homeostasis or to repair tissues after injury. When 
homeostatic control diminishes to a point at which 
tissue/organ integrity and function are no longer 
sufficiently maintained, physiologic decline ensues, and 
aging is manifested. Consistent with this, many of the 
pathophysiological conditions afflicting the elderly, 
such as anemia, sarcopenia and osteoporosis, suggest an 
imbalance between cell loss and renewal.  
 
Numerous theories have been put forth to explain the 
decline of stem cell function with advancing age. The 
free-radical theory of aging proposes that reactive 
oxygen species (ROS), which are by-products of normal 
metabolism, are responsible for damage to many cellu-





































that in addition to ROS, a much broader range of 
extrinsic and intrinsic sources, such as UV irradiation, 
alkylating agents, telomere attrition, and DNA 
replication errors, can also infringe upon genomic 
integrity [2]. In response to this damage, tumor 
suppressor pathways are activated, including those 
mediated by the tumor suppressor proteins p16 and p53, 
to ensure that potentially dangerous lesions do not lead 
to malignancy [2,3]. So, when aging advances and 
damage accumulates the activity of these tumor 
suppressors increases and consequently has the potential 
to negatively modulate stem cell function through the 
induction of apoptosis or senescence.  
 
p16
INK4a and aging 
 
The cyclin-dependent kinase inhibitor p16
INK4a has 
emerged as an important player in aging and age-related 
disease. p16
INK4a has the ability to bind and inhibit the 
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kinases are known to have oncogenic potential and 
phosphorylate the retinoblastoma (Rb) family of tumor 
suppressors. Hence, expression of p16
INK4a maintains 
Rb-family proteins in hypophosphorylated state, which 
promotes binding of E2F to effect a G1 cell cycle arrest 
[3,4]. Several studies have shown that p16
INK4a 
expression increases markedly with advancing age in a 
variety of tissues [5-8]. Consequently, the increased 
expression of p16
INK4a  induces an age-dependent 
decrease in the proliferative capacity of certain tissue-
specific stem- and progenitor-cells [5-8]. Senescence 
characterized by p16
INK4a upregulation as well as 
telomere shortening has been observed in human and 
mouse cardiomyocytes and may contribute to 
myocardial aging [9,10]. Because p16
INK4a expression 
can be upregulated by a wide variety of stresses [4,11] it 
may be involved in many, maybe all, forms of 
senescence, and has thus recently received attention as a 
promising biomarker [12,13]. 
 
Also in the hematopoietic system it has been shown that 
the induction of p16
INK4a correlated with the in vivo 
senescence of hematopoietic stem cells [14-16]. Indeed, 
mice lacking BMI1, a repressor of p16
INK4a, displayed a 
striking loss of hematopoietic cells which correlated 
with increased expression of p16
INK4a expression and 
replicative failure of stem cells [16-18]. Conversely, an 
increase in regenerative capacity was found in the bone 
marrow of p16
INK4a deficient mice [19]. These findings 
reinforce the notion that the age-associated upregulation 
of p16
INK4a restricts self-renewal and unbalances tissue 
homeostasis. We have confirmed increased p16
INK4a 
expression in healthy human CD34+ hematopoietic 





















Aging and Acute Myeloid Leukemia 
 
Aging not only affects normal hematopoietic 
development (e.g. increased incidence of anemia), but 
also impacts on the clinical biology of AML. In 
particular, the incidence of AML increases with 
increasing age [21,22]. Moreover, older AML patients 
have a markedly reduced long-term survival due to the 
combination of poor chemotherapeutic tolerance and 
inherent chemotherapy resistance compared to younger 
AML patients [21-25]. AML in older patients shows 
also a lower frequency of favorable core-binding 
chromosomal abnormalities and a higher incidence of 
complex aberrant karyotypes [26,27]. We wondered 
whether these differences in clinical and cellular 
behavior of AML in older patients were reflected by 
differences in gene expression profiles. Therefore, a 
cohort of 525 adult AML patients was studied to 
compare gene expression profiles of the one-third of 
youngest cases (median age 31 years) with the one third 
of oldest cases (median age 59 years) [20]. Biological 
processes (represented by GO-ontologies) associated 
with aging in AML were compared with a published list 
of significantly differentially expressed GO-ontologies 
between young and old purified murine long-term 
hematopoietic stem cells. This analysis revealed that in 
both sets the NF-κB cascade was up-regulated and that 
maintenance of chromatin architecture, chromatin 
modification and organelle organization were down-
regulated [20, 28]. Subsequently, comparison of gene 
expression profiles of AML samples of the 175 
youngest with the 175 oldest AML patients revealed 
that 477 probe sets were up-regulated and 492 probe 
sets were down-regulated with increasing age at the 


















Cancer type  age  n  P  Rho 
 
lymphoma   61 (2-61)  219  <.001  -.252 
 
glioblastoma   52 (26-70)  80  .005  -.310 
 







The  relation  between  the  expression  of  p16
INK4a  mRNA  level  and  age  at
diagnosis in three malignancies (publicly available micro arrays, i.e. GSE4475,
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validation. The final list of validated genes which were 
differently expressed depending on age in three 
independent AML cohorts yielded a number of 
interesting genes, including p16
INK4a. The level of 
expression of p16
INK4a in AML samples during aging 
was reciprocal to the usual trend of an increased 
expression at higher age; i.e. the expression of p16
INK4a 
declined significantly with increasing age. Of note, this 
was only noticed in the intermediate- and unfavorable-
risk group and not in the favorable-risk group and the 
molecularly defined subset ‘NPM1 mutant without 
FLT3-ITD’. Multivariate analysis revealed p16
INK4a, 
besides cytogenetic risk-groups, as an independent 
prognostic parameter for overall survival (OS) in older 
(and not in younger) AML patients. Lower p16
INK4a 
expression in AML samples of patients of older age 
predicts for reduced OS. Further studies unraveling the 
regulation and molecular mechanisms responsible for 
the down-regulation of p16
INK4a during aging in AML 
are awaited. Striking in this perspective is our 
observation that BMI1, a potent repressor of p16
INK4a, 
was significantly inversely correlated with p16
































older (P = <.001, rho = -.274, n = 175) and not in 
younger (P = .322, rho = -.075, n = 175) AML patients. 
 
Is the downregulation of p16
INK4a a broader 
phenomenon? 
 
We wondered whether the paradoxical down-regulation 
of p16
INK4a with advancing age in AML might be a more 
general phenomenon, i.e. is p16
INK4a expression also 
down-regulated with advancing age in other 
malignancies? An extensive search in the Gene 
Expression Omnibus (GEO) repository revealed only 
three publically available Affymetrix gene array 
datasets of malignancies (i.e. lymphoma, glioblastoma 
and breast cancer) which also presented the patient 
characteristic age (GSE4475, GSE7696 and GSE3494) 
[29-31]. The median age at diagnosis is given in Table 1 
for all three cohorts. Interestingly, the expression of 
p16
INK4a declined significantly with advancing age in 
lymphoma patient samples (P = <.001, rho = -.252 n = 
219, Table 1) and in glioblastoma patient samples (P = 
.005, rho = -.310, n= 80, Table 1). In breast cancer 
patient samples the continuous variables age and p16
INK4a 
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The cyclin-dependent kinase inhibitor p16
INK4a, which 
has emerged as an important effector of aging and a 
potent tumor suppressor, was shown to be down-
regulated in older AML samples [20].  However, this is 
not unique for AML since the paradoxical down-
regulation with advancing age is also observed in 
samples from lymphoma and glioblastoma patients. 
These observations provide an interesting new link 
between aging and cancer. We hypothesize that suppres-
sion of defense mechanisms which protect older cells 
against cellular and DNA damage might facilitate onco-
genesis in cancer cells from older individuals (Figure 1). 
Accordingly, the interaction between aging and cancer 
warrants further studies, to determine whether age-asso-
ciated protection mechanisms play a specific role in 
cancer of older patients and to determine whether modu-
lation of these age-associated protection mechanisms can 
be exploited in the treatment of older cancer patients.  
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